For research use only. Not for therapeutic Use.
Fulimetibant is a bradykinin receptor antagonist[1].
| Catalog Number | I043406 |
| CAS Number | 2231142-90-6 |
| Synonyms | 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid |
| Molecular Formula | C25H21F4N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H21F4N3O3/c26-21-10-15(25(27,28)29)4-7-20(21)24(8-9-24)23(35)31-16-5-6-18(19(11-16)22(33)34)14-12-30-32(13-14)17-2-1-3-17/h4-7,10-13,17H,1-3,8-9H2,(H,31,35)(H,33,34) |
| InChIKey | DFQFSWDEFZCQLH-UHFFFAOYSA-N |
| SMILES | C1CC(C1)N2C=C(C=N2)C3=C(C=C(C=C3)NC(=O)C4(CC4)C5=C(C=C(C=C5)C(F)(F)F)F)C(=O)O |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022. |
